top of page
Search

Know Labs receives NYSE American listing approval

  • The Company’s technology uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature.


  • The Company refers to its technology as Bio-RFID™.


  • The Bio-RFID technology can be integrated into a variety of wearable, mobile or bench-top form factors.


Boustead Securities, LLC (“Boustead”) client Know Labs, Inc. (OTCQB: KNWN), an emerging developer of non-invasive medical diagnostic technology, today announced that, subject to official authorization and meeting all requirements (including the price requirement) at the time of listing, the Company has been approved to uplist to the NYSE American Exchange in conjunction with an underwritten public offering of the Company’s common stock.


Upon the start of trading on the NYSE American, the ticker symbol for Know Labs’ common stock will change from “KNWN” to “KNW” and the Company’s common stock will cease trading on the over-the-counter (OTC) market. The stock is expected to commence trading on NYSE American at the opening of trading on September 16, 2022.“


The Know Labs team has been working hard to build what we believe will be the first non-invasive FDA-cleared blood glucose monitoring device,” said Ron Erickson, Know Labs Chairman. “The uplist to a major national exchange is consequence of their work. I would like to thank our team members for their effort and our shareholders for their continued support. We remain focused on transforming the medical diagnostics industry.”About Know Labs, Inc.


Know Labs, Inc. is a public company whose shares trade under the stock symbol “KNWN.” The Company’s technology uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. The Company refers to its technology as Bio-RFID™. The Bio-RFID technology can be integrated into a variety of wearable, mobile or bench-top form factors. This patented and patent pending technology makes it possible to effectively conduct analyses that could only previously be performed by invasive and/or expensive and time-consuming lab-based tests. The first application of our Bio-RFID technology will be in a product marketed as a glucose monitor. It will provide the user with real time information on their blood glucose levels. This product will require US Food and Drug Administration approval prior to its introduction to the market.



Source: Boustead Securities

bottom of page